Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer

PURPOSE: The role of neoadjuvant endocrine therapy in the treatment of patients with early-stage, hormone receptor-positive (HR +) breast cancer is not well defined. Tools to better determine which patients may benefit from neoadjuvant endocrine therapy versus chemotherapy or upfront surgery remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Caitlin, Meisel, Jane, Foreman, Aimee J., Russell, Christy, Bandyopadhyay, Dipankar, Deng, Xiaoyan, Floyd, Lisa, Zelnak, Amelia, Bear, Harry, O’Regan, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147793/
https://www.ncbi.nlm.nih.gov/pubmed/36897465
http://dx.doi.org/10.1007/s10549-023-06890-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147793/
https://www.ncbi.nlm.nih.gov/pubmed/36897465
http://dx.doi.org/10.1007/s10549-023-06890-7

Ejemplares similares